Gapping up
In reaction to earnings/guidance:
- LEVI +5.5% (also increases dividend), AFYA +2.2% (also announces acquisition of Medical Harbour), SMG +1.4% (raises FY21 rev guidance above consensus; raises EPS guidance above consensus at the mid-point)
Other news:
- CELC +52.7% (PFE announces licensing agreement with CELC for gedatolisib)
- GLSI +29% (reports Phase IIb data supporting GP2 clinical outcome of 0% metastatic breast cancer recurrences over 5 years)
- AFMD +27.5% (presents Phase 1 study of cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13 at AACR)
- LHDX +14.6% (confirmed it can successfully identify the "double mutant" variant of COVID-19 with its Lucira molecular test kit)
- TXMD +9.1% (announces approvals for BIJUVE in the UK and Belgium)
- FUBO +8.4% (acquires streaming rights to the Qatar World Cup 2022)
- SOGO +6% (reports circulate that China's antitrust regulators are poised to clear Tencent's (TCEHY) buyout of SOGO)
- TRQ +4.2% (Turquiose Hill Resources and Rio Tinto (RIO) signs agreement for funding Oyu Tolgoi)
- RDHL +4% (reports Phase 2/3 COVID-19 study of Opaganib passes fourth DSMB review)
- SUNW +3.4% (to acquire Solcius)
- HGEN +3.1% (announces positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme)
- IOVA +2.8% (announced data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma)
- GSX +2.8% (firmly denies the false and ungrounded allegations raised in a report by Grizzly Research; believes report contains numerous errors, unsubstantiated statements, and misinterpretation of information)
- UPST +2.6% (prices follow-on offering of 2 mln shares of common stock at $120.00 per share)
- NBIX +2.5% (to present data from its Neurology portfolio)
- BKD +2% (reports March occupancy metrics)
- CCK +2% (to sell its European Tinplate business to KPS Capital for €1.9 bln; also to sell its EMEA food and consumer packaging business to KPS Capital for €2.25 bln)
- JCI +1.5% (acquires Silent-Aire; to be immediately accretive to FY22 earnings)
Analyst comments:
- DAN +2.7% (upgraded to Overweight from Equal Weight at Barclays)
- CCL +2.1% (upgraded to Outperform from Neutral at Credit Suisse)
- COMM +2.1% (upgraded to Buy from Neutral at Rosenblatt)
- OKTA +2.1% (upgraded to Buy from Neutral at BTIG Research)
- HON +2% (upgraded to Buy from Hold at Deutsche Bank)
- PM +1.3% (upgraded to Overweight from Neutral at JP Morgan)
- IBA +1.1% (upgraded to Overweight from Neutral at JP Morgan)